Metraipolis › archive › dc_ebe7dbcf0b0e

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis — Europe PMC PMID:42081291

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42081291
DOI
10.1093/oncolo/oyag172
License (as archived)
solo-consultazione
Archived
2026-11-02T22:50:38.741Z
SHA-256 of the archived text
d0d0af665608b3aeeacece23ce493563344feab3907efe81f61c300274045073
Stable URL of this page
https://metraipolis.com/documento/dc_ebe7dbcf0b0e

How to cite

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis — Europe PMC PMID:42081291 — Europe PMC (en), https://europepmc.org/article/MED/42081291 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ebe7dbcf0b0e (Metraipolis archive dc_ebe7dbcf0b0e, sha256 d0d0af665608b3aeeacece23ce493563344feab3907efe81f61c300274045073)
BibTeX
@misc{dcebe7dbcf0b0e,
  title = {Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis — Europe PMC PMID:42081291},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42081291},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ebe7dbcf0b0e; sha256 d0d0af665608b3aeeacece23ce493563344feab3907efe81f61c300274045073},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42081291. Agents can read the archived copy with the MCP tool read_document.